FindTrial
Sign In

IBI310

DRUG10 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., Peking University, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Conditions

Advanced Biliary Tract CancerAdvanced Cervical CancerAdvanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaAdvanced Solid TumorsHealthy SubjectsHepatocellular CarcinomaHepatocellular Carcinoma (HCC)NPC

Phase 1

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
CompletedNCT03545971
Innovent Biologics (Suzhou) Co. Ltd.Advanced Solid Tumors
Start: 2018-09-25End: 2022-08-09Updated: 2023-02-28
Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer
NCT04202601
Peking UniversityAdvanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Start: 2019-12-13End: 2022-12-01Target: 80Updated: 2019-12-19
A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers
CompletedNCT04868760
Innovent Biologics (Suzhou) Co. Ltd.Healthy Subjects
Start: 2021-05-31End: 2022-05-02Updated: 2025-04-13
IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC
CompletedNCT04945421
Innovent Biologics (Suzhou) Co. Ltd.NPC
Start: 2021-07-23End: 2023-02-06Updated: 2023-02-23
IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
CompletedNCT05118334
Innovent Biologics (Suzhou) Co. Ltd.NSCLC (Non-small-cell Lung Cancer)
Start: 2021-11-12End: 2023-02-17Updated: 2023-02-23
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
NCT05653180
Innovent Biologics (Suzhou) Co. Ltd.Advanced Biliary Tract Cancer
Start: 2023-03-10End: 2024-06-01Target: 20Updated: 2023-04-03

Phase 2

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy
CompletedNCT04590599
Innovent Biologics (Suzhou) Co. Ltd.Advanced Cervical Cancer
Start: 2020-12-08End: 2023-11-20Updated: 2023-12-18
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)
RecruitingNCT05165407
Peking UniversityNeuroendocrine Neoplasm
Start: 2022-07-12End: 2025-09-30Target: 30Updated: 2025-03-14
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
RecruitingNCT07490262
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Hepatocellular Carcinoma (HCC)
Start: 2026-03-27End: 2030-12-31Target: 680Updated: 2026-04-16

Phase 3

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
CompletedNCT04720716
Innovent Biologics (Suzhou) Co. Ltd.Hepatocellular Carcinoma
Start: 2021-02-07End: 2025-12-31Updated: 2026-03-19

Related Papers

Effectiveness and safety of IBI310 combined with sintilimab versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, controlled, multicenter phase III clinical study.
Journal of Clinical Oncology2026-05-27
Surufatinib combined with sintilimab and IBI310 for the treatment of high-grade advanced-neuroendocrine neoplasms: A single arm, open-label, single-center, phase II study.
2025-12-29
Updated results from a multicenter, single-arm phase II study of surufatinib plus sintilimab and IBI310 in patients with high-grade advanced-neuroendocrine neoplasm (HG-NEN).
Journal of Clinical Oncology2025-05-28
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial.
2025-01-183 citations
Abstract CT079: Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial
Cancer Research2023-04-141 citations
IBI310 monotherapy or in combination with sintilimab in patients with advanced melanoma: An open-label phase Ia/1b study.
Journal of Clinical Oncology2020-05-201 citations